Table 2.

Clinical parameters of EAE in mice treated with anti-CD20 or respective isotype control antibodies.

Cohort	Treatment	Number of Mice	EAE Onset (Days after Immunisation)	Maximum Score	Mean Severity after Onset	Score at Beginning of Treatment	Score at End of Treatment	Score Difference before and after Treatment
wt	huIgG2a	6	12.17 ± 1.25	2.92 ± 0.08	2.20 ± 0.15	2.00 ± 0.18	2.00 ± 0.26	0.00 ± 0.13
	18B12	7	11.57 ± 0.48	2.93 ± 0.07	2.16 ± 0.09	1.93 ± 0.20	1.64 ± 0.21	−0.29 ± 0.10
p value			0.88	>0.99	>0.99	0.73	0.39	0.18
CD20dbtg1	huIgG1	6	16.67 ± 1.33	2.67 ± 0.17	1.97 ± 0.19	2.33 ± 0.17	1.75 ± 0.21	−0.58 ± 0.24
	OBZ	6	15.17 ± 0.65	2.75 ± 0.11	2.25 ± 0.13	2.33 ± 0.11	2.17 ± 0.17	−0.17 ± 0.11
p value			0.37	>0.99	0.59	>0.99	0.25	0.28
CD20dbtg2	huIgG1	6	22.67 ± 8.08	2.50 ± 0.18	1.65 ± 0.29	1.33 ± 0.33	1.92 ± 0.20	0.58 ± 0.40
	OBZ	6	23.33 ± 7.08	2.38 ± 0.18	1.46 ± 0.34	1.33 ± 0.40	1.50 ± 0.34	0.17 ± 0.38
p value			0.55	0.74	0.48	>0.99	0.40	0.47

Values are displayed as mean values ± standard error of the mean (SEM). Statistical significance was determined using the Mann–Whitney U test.